Operating Income (Loss) in USD of Nabriva Therapeutics plc from 2014 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Nabriva Therapeutics plc quarterly/annual Operating Income (Loss) history and change rate from 2014 to Q2 2023.
  • Nabriva Therapeutics plc Operating Income (Loss) for the quarter ending 30 Jun 2023 was -$12M, a 15.6% decline year-over-year.
  • Nabriva Therapeutics plc Operating Income (Loss) for the twelve months ending 30 Jun 2023 was -$54M, a 18.3% decline year-over-year.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2022 was -$55.5M, a 14.3% decline from 2021.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2021 was -$48.5M, a 26.6% increase from 2020.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2020 was -$66.1M, a 16.8% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Nabriva Therapeutics plc Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$54M -$12M -$1.63M -15.6% 01 Apr 2023 30 Jun 2023 10-Q 19 Oct 2023
Q1 2023 -$52.4M -$8.48M +$3.08M +26.7% 01 Jan 2023 31 Mar 2023 10-Q 22 May 2023
Q4 2022 -$55.5M -$22.3M -$9.45M -73.3% 01 Oct 2022 31 Dec 2022 10-K 17 Apr 2023
Q3 2022 -$46M -$11.2M -$388K -3.59% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022
Q2 2022 -$45.7M -$10.4M +$983K +8.64% 01 Apr 2022 30 Jun 2022 10-Q 19 Oct 2023
Q1 2022 -$46.6M -$11.6M +$1.89M +14.1% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023
Q4 2021 -$48.5M -$12.9M +$5.38M +29.5% 01 Oct 2021 31 Dec 2021 10-K 17 Apr 2023
Q3 2021 -$53.9M -$10.8M +$2.4M +18.2% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$56.3M -$11.4M +$3.07M +21.2% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022
Q1 2021 -$59.4M -$13.4M +$6.74M +33.4% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 -$66.1M -$18.3M +$3.8M +17.2% 01 Oct 2020 31 Dec 2020 10-K 17 Apr 2023
Q3 2020 -$69.9M -$13.2M +$3.98M +23.2% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021
Q2 2020 -$73.9M -$14.5M +$6.52M +31.1% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 -$80.4M -$20.2M -$944K -4.91% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 -$79.5M -$22.1M +$8.81M +28.5% 01 Oct 2019 31 Dec 2019 10-K 12 Mar 2020
Q3 2019 -$88.3M -$17.2M +$35.7M +67.5% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$124M -$21M -$3.27M -18.5% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 -$121M -$19.2M -$6.38M -49.6% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020
Q4 2018 -$114M -$30.9M -$8.6M -38.6% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020
Q3 2018 -$106M -$52.9M -$32.2M -155% 01 Jul 2018 30 Sep 2018 10-K 12 Mar 2020
Q2 2018 -$73.6M -$17.7M -$2.15M -13.8% 01 Apr 2018 30 Jun 2018 10-K 12 Mar 2020
Q1 2018 -$71.4M -$12.9M +$2.34M +15.4% 01 Jan 2018 31 Mar 2018 10-K 12 Mar 2020
Q4 2017 -$73.8M -$22.3M -$7.54M -51.2% 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019
Q3 2017 -$66.2M -$20.7M -$6.65M -47.2% 01 Jul 2017 30 Sep 2017 10-K 12 Mar 2019
Q2 2017 -$59.6M -$15.6M -$4.04M -35% 01 Apr 2017 30 Jun 2017 10-K 12 Mar 2019
Q1 2017 -$55.5M -$15.2M -$498K -3.39% 01 Jan 2017 31 Mar 2017 10-K 12 Mar 2019
Q4 2016 -$55M -$14.7M -$4.5M -43.9% 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2018
Q3 2016 -$50.5M -$14.1M -$5.75M -69.1% 01 Jul 2016 30 Sep 2016 10-K 16 Mar 2018
Q2 2016 -$44.8M -$11.5M -$6.01M -109% 01 Apr 2016 30 Jun 2016 10-K 16 Mar 2018
Q1 2016 -$38.8M -$14.7M -$11M -301% 01 Jan 2016 31 Mar 2016 10-K 16 Mar 2018
Q4 2015 -$27.8M -$10.2M 01 Oct 2015 31 Dec 2015 10-K 24 Mar 2017
Q3 2015 -$8.33M 01 Jul 2015 30 Sep 2015 10-K 24 Mar 2017
Q2 2015 -$5.52M 01 Apr 2015 30 Jun 2015 10-K 24 Mar 2017
Q1 2015 -$3.67M 01 Jan 2015 31 Mar 2015 10-K 24 Mar 2017

Nabriva Therapeutics plc Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$55.5M -$6.96M -14.3% 01 Jan 2022 31 Dec 2022 10-K 17 Apr 2023
2021 -$48.5M +$17.6M +26.6% 01 Jan 2021 31 Dec 2021 10-K 17 Apr 2023
2020 -$66.1M +$13.4M +16.8% 01 Jan 2020 31 Dec 2020 10-K 17 Apr 2023
2019 -$79.5M +$34.9M +30.5% 01 Jan 2019 31 Dec 2019 10-K 29 Mar 2022
2018 -$114M -$40.6M -55% 01 Jan 2018 31 Dec 2018 10-K 11 Mar 2021
2017 -$73.8M -$18.7M -34% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2020
2016 -$55M -$27.3M -98.3% 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2019
2015 -$27.8M -$17.1M -160% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2018
2014 -$10.7M 01 Jan 2014 31 Dec 2014 10-K 24 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.